Two Midcap Hospital & Pharma Stocks Declared Dividend, Trading Near 52-Week Low, Should You Buy?

Two Midcap stocks recently declared Interim dividends are trading near their 52 week low. These stocks are Natco Pharma Ltd. and Metropolis Healthcare Ltd. ICICI Securities, a leading brokerage firm has placed a "Buy" on Natco Pharma with a positive outlook, claims gain more than 50% if purchased at the current market price. Check details:

Natco Pharma Ltd Declared Interim Dividend

According to the regulatory filing by the Board of Directors of the company on February 9, 2023, "Declared 3rd interim dividend of Rs. 1.25 (one rupee twenty-five paise only i.e., 62.50%) each per equity share of Rs.2/- {Rupees two only} each for the financial year 2022-23. The date for taking on record of its shareholders eligible for the purpose of payment of 3rd Interim dividend i.e., record date is fixed as Tuesday, the 21st day of February, 2023. The payment of said interim dividend will be from 1st March, 2023."

 

Natco Pharma - Stock Overview

The share price of Natco Pharma is currently trading at Rs 531.45/share on NSE. It is trading 5.87% up from its 52 week low which is Rs 502/share. The stock's 52 week high is Rs 938.80/share. Its market capitalisation is Rs 9,713.87 crore.

The stock declined 3.93% in 1 month, and 7.25% in 3 months, respectively. It declined 42.03% in 1 year, 21.39% in 3 years and 32.15% in 5 years, respectively. However, in the past 1 week, it gained 0.57%.

 

Natco Pharma - ICICI Securities says "Buy" for Rs 816/share

ICICI Securities with the given target price and the Current Market Price claims a robust gain of up to 54%.

The brokerage said, "We maintain our revenue and EPS estimates for FY24EFY25E. Maintain BUY on the stock with SoTP-based revised target price of Rs816/share including NPV of Rs259/share for Revlimid and Rs77/share for Imbruvica."

According to the brokerage the key downside risks are Delay in US launches, increased competition in Copaxone and Revlimid.

 

Metropolis Healthcare Ltd Declared Interim Dividend

According to the exchange filing by the company on February 10, 2023, "Approved and Declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight Only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two Only) per Equity Share for the Financial Year 2022-23. The Board has fixed Thursday. February 23, 2023, as the "Record Date" for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend. The Interim Dividend will be paid to the shareholders within 30 days of declaration."

 

Metropolis Healthcare Ltd - Stock Performance

The stock of Metropolis Healthcare is currently trading at Rs 1,317.85/share. It is trading 10.71% up from its 52 week low of Rs 1190.40/share. Its 52-week high is Rs 2570.60/share. Its market valuation is Rs 6,746.69 crore.

The stock has given 5.25% positive return in the past 1 week. However, in the past 1 and 3 months, it declined by 4.64% and 16.59%, respectively. In 1 year it declined by 35.88% and in 3 years it declined by 25.68%, respectively.

 

Disclaimer

The stocks have been picked from the brokerage report of ICICI Securities. Greynium Information Technologies, the Author, and the respective Brokerage house are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to consult with certified experts before making any investment decision.